Dr. Jerry Shapiro to Present RepliCel Data to European Academy of Dermatology and Venereology in Poland
VANCOUVER, BC – May 23, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX: RP), reports that one of its founders, Dr. Jerry Shapiro, MD, FRCPC, will be presenting RepliCel’s Phase I safety data and the concept of using dermal sheath cup cells for hair growth at the 10th European Academy of Dermatology and Venereology (EADV) Spring Symposium in Cracow, Poland on May 25th at 12:00 PM local time. The focus of the conference is on the “burden of skin disease”.
“The RepliCel data from its RCH-01 Phase I trial treating pattern baldness is very promising,” commented Dr. Shapiro, one of RepliCel’s founders. “The trial provided the Company with safety and early efficacy data supporting a progression to the next phase. RepliCel’s proposed Phase II dose-ranging study is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants and will provide over 288 data points as compared to 16 in the Phase I trial. The Phase II trial should determine what the optimum dose is to promote hair growth,” concluded Dr. Shapiro.
About Dr. Jerry Shapiro
Dr. Shapiro is one of the most experienced hair dermatologists in the world and has specialized in hair disorders for the past 22 years. He holds dual academic appointments as Clinical Professor and Adjunct Professor at both the University of British Columbia and New York University School of Medicine. Dr. Shapiro is the founder of the first comprehensive integrated medical and surgical hair clinic in the world. He has trained over thirty international hair fellows from four continents. He has published over 100 peer-reviewed papers, 15 book chapters and two books. He has lectured internationally on hair related topics on 173 occasions on 6 continents.
About the European Academy of Dermatology and Venereology
The EADV is a non-profit association founded in 1987 whose mission is to advance excellence in clinical care, research, education and training in the field of dermatology and venereology and to act as the advocate and educator of patients particularly those with cutaneous or venereal diseases. The EADV organizes annually, one main congress in one of the European capitals and one spring meeting. It also offers training, courses and online teaching for continuing medical education. For more information please visit www.eadvcracow2013.org
About RepliCel Life Sciences
The Company is developing two autologous cell therapies. The first is a cellular treatment for androgenetic alopecia (pattern baldness) named RepliCel Hair-01 (RCH-01). The second is a cell therapy for the treatment of chronic tendon injuries named RepliCel Tendon-01 (RCT-01). Both treatments are based on RepliCel’s innovative technology which utilizes cells isolated from a patient’s own healthy hair follicles to address specific cellular deficits. Phase II clinical trials, for both technologies, are planned for the later part of 2013.
For more information please contact:
Tammey George, Director of Communications
Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements that relate to the approval and commercialization of the Company’s hair restoration process, the Company’s development of its Achilles tendon technology and the expected commencement of the Company’s Phase II clinical trial for its tendon technology. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company’s clinical trials; the effects of government regulation on the Company’s business; risks associated with the Company’s ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company’s ability to raise additional capital; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2012 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on Sedar at www.sedar.com
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.